ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. We now have a well-defined process to take things from ideation to in vivo animal proof of concept studies before handing them off to product development. Of special note are the following publications: To browse the literature, please see the curated list at PubMed. Immunomic Therapeutics is a biotech company committed to patients. 2003 Sep 26;278(39):37926-36. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). Brians specific and deep knowledge of cell therapy manufacturing and operations will be invaluable as we prepare for phase 3 testing of ITI-1000, our lead dendritic cell therapy for the treatment of glioblastoma multiforme (GBM).. ITI maintains its headquarters in Rockville, Maryland. Copied Should we find that your skills and experience match our position needs, a Immunomic Therapeutics, Inc. representative will contact you to discuss the opportunity. GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Last Funding Type Venture - Series Unknown. The therapy was developed using ITIs proprietary UNITE (UNiversal Intracellular Targeted Expression) platform. Immunomic Therapeutics considers applicants for all positions without regard to race, color, creed, religion, ancestry, national origin, age, gender identity, sex, marital status, sexual orientation, physical or mental disability, use of a guide dog or service animal, military/veteran status, citizenship status, basis of genetic information, or any other group protected by law. View detailed 028300.KR description & address. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Sampson and Mitchell in the development of a new approach to attack Glioblastoma Multiforme (GBM). 2016;2016:4857869. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC). SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. ITI-1000 is currently being investigated in a Phase 2 ATTAC-II trial at UF and Duke. We are also collaborating with academic centers and biotechnology companies to study the use of the UNITE platform in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma. View contacts for Immunomic Therapeutics to access new leads and connect with decision-makers. Amy Conrad A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Please include the Job Code in the subject line and attach a cover letter and salary requirement along with a current resume to complete your candidacy submission for each position in which you are interested. Find all information and best deals of Chinatrust Executive House Hsin-Tien, New Taipei City on Trip.com! Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bodys natural biochemistry to develop vaccines that generate broad immune responses. Su Y et al., CryJ-LAMP DNA Vaccines for Japanese Red Cedar Allergy Induce Robust Th1-Type Immune Responses in Murine Model. Glassdoor gives you an inside look at what it's like to work at Immunomic Therapeutics, including salaries, reviews, office photos, and more. Their LAMP-Vax platform is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in . Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines for the treatment of allergy and other human health targets. Join to connect Immunomic Therapeutics, Inc. Mount Saint Mary's College. Where the organization is headquartered (e.g. Active, Closed, Last funding round type (e.g. amy@juniper-point.com Active, Closed, Last funding round type (e.g. Over 100 studies have been published on LAMP, ranging from those focused on the fundamental biology of lysosomal associated membrane protein to the immunobiology of novel vaccine candidates. 301-968-3501 Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. Work Here? Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. The company is developing three small molecule products; its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of. The initial foray into immuno-oncology was undertaken when ITI decided to support the work of Drs. ITI-2000 HPV+ Tumors. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. Those studies had enrolled all comers, and Bristol restricted Checkpoint-548's enrolment to patients carrying the MGMT methylation biomarker in . We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. Ms. Harrison brings to the company more than 30 years of experience in global regulatory strategies and submissions, interactions, intelligence and advocacy. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. While induction of tumor-reactive CD8+ T cells is a major goal of cancer therapy, CD4+ T cells provide essential support to CD8+ T cells by promoting their expression of cytotoxic effector molecules and increasing their migratory capacity. You will receive a reply to confirm the receipt of your application. Founders Sungwuk Kim. Ms. Harrison earned a Bachelor of Science in Biochemistry from San Diego State University. Immunomic Therapeutics to Present at Biotech Showcase 2023, PharmaJet Partner Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancer, ITI Receives FDA Fast Track Designation for ITI-3000, ITI Announces Presentation on Nucleic Acid-Based UNITE Vaccine Platform at Vaccines Summit 2022. They have a proven track record of success in Asia and share our commitment and passion for developing best-in-class therapies for cancer and other serious diseases, said Dr. William Hearl, CEO of Immunomic Therapeutics. You are here: hackberry allergy symptoms; 49ers paying players under the table; immunomic therapeutics crunchbase . aanagnostou@immunomix.com The work and relationships that Louise has fostered over the years position us for successful meetings in the future and I look forward to contributing meaningfully to the companys future regulatory interactions to further advance ITIs development programs utilizing the innovative and proprietary UNITE technology platform.. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. This is the Immunomic Therapeutics company profile. Immunomic Therapeutics General Information. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal Intracellular Targeted Expression (UNITE), which is designed to utilize the bo dy's natural biochemistry to develop . The Phase 2 protocol will remain active, the existing Principal Investigators (PIs . Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Total number of organizations similar to the given organization, Descriptive keyword for an Organization (e.g. Clin Cancer Res. Hum Vaccin Immunother. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . This is the Immunomic Therapeutics company profile. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. The majority of Merkel cell carcinomas (MCC), a rare but aggressive form of skin cancer, are associated with MCPyV infection, making LT an attractive target for this cancer vaccine. We believe that these early clinical studies may provide a proof of concept for UNITE in cancer, and if successful, set the stage for future studies, including combinations in this tumor type and others. If you enjoy the challenge that goes naturally with being part of a high growth company, then a career with Immunomic Therapeutics, Inc. may be just for you. Brian joins the company with over 20 years of experience in cell therapy operations, pharmaceutical manufacturing, and process engineering. ImmunoMet Therapeutics is a biopharmaceutical company that develops and commercializes oncology products for cancer patients. We are looking for passionate individuals who want to create leading edge technology, thrive in an intellectually stimulating environment, and make a difference in healthcare outcomes. ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the close of a $61.3M financing led by HLB Co., LTD, a global pharmaceutical company focused on developing novel cancer drugs. In addition to TH1 response, we also observe antigen specific antibodies indicative of TH2 response further enhancing the anti-tumor potential of this vaccine.ITI-1001 presents an alternative for patients that missed the treatment window for other therapies or that cannot produce enough cells to start cell therapy manufacturing (~30% of patients). To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Preclinical research data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Very family oriented. 858-366-3243, Internet Explorer presents a security risk. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Contact Email info@immunomet.com. AAPL, FB, TWTR), Total amount raised across all funding rounds, Total number of Crunchbase contacts associated with this organization, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. ITIs lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy. J Immunol Res. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy and autoimmune diseases. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. 917-322-2571, Internet Explorer presents a security risk. Jan 30, 2015. Company: Melissa Kemp Immunomic Therapeutics Mkemp@immunomix.com 301-968-3501 Media: Amy Conrad Juniper Point amy@juniper-point.com 858-366-3243 Contacts Harnessing the immune system to achieve deep and durable clinical responses in cancer. 2017 Aug;47:85-92. pipeline of metabolic regulators preferentially targeting the cellular metabolism of drug-resistant cancer subpopulations and immuno-suppressors of anti-cancer effector T cells. Innovative Cellular Therapeutics (ICT) is a clinical-stage, VC-backed cell therapy company based in Rockville, MD. This feature is in beta and may change with future updates. ITI-1001 GBM - pDNA. ITIs UNITE platform combines its core lysosomal targeting technology with novel formulation, delivery, and adjuvant complements. November 30, 2021, 7:01 PM UTC. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. 2020 Immunomic Therapeutics, Inc. All Rights Reserved. The company was founded in 2005 and is based in Lancaster, Pennsylvania. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. To explore Immunic Therapeutics's full profile, request access. Concurrent with the financing, five (5) members from HLB Co., LTD will be joining the Immunomic Therapeutics Board of Directors. Immunomic Therapeutics, Inc. | 2,335 followers on LinkedIn. On behalf of the management team, I am pleased to welcome Ms. Harrison to ITI. January 04, 2023 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, announced today that, Vaccine exclusively delivered with the PharmaJet StratisNeedle-free Injection System December 13, 2022 11:00 AM Eastern Standard Time GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet, a company that engineers precision delivery systems that overcome, November 08, 2022 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held clinical-stage biotechnology company pioneering the development of LAMP-mediated nucleic acid-based immunotherapy, today announced, October 10, 2022 09:00 AM Eastern Daylight Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (ITI), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy announced today. ITIs investigational UNITE platform, or UNiversal Intracellular Targeted Expression, works by fusing pathogenic antigens with the Lysosomal Associated Membrane Protein, an endogenous protein in humans, for immune processing. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. To ensure the most secure and best overall experience on our website we recommend the latest versions of, Internet Explorer is no longer supported. Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company revolutionizing the study of the Lysosomal Associated Membrane . CFO at Immunomic Therapeutics, Inc. Germantown, Maryland, United States. Pay, Holidays and PTO appear to be very good. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Share this article. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. 15010 Broschart Dr., Suite 110, Rockville, MD 20850. We provide a professional and challenging work environment where employees can grow and share in the continued success of the company. 2017 Apr 15;23(8):1898-1909. 15010 Broschart Road Suite 250. This represents the second closing in the investment process for the HLB Consortium, ($10M was placed in February 2020), and substantially increases their holding in Immunomic Therapeutics to 47.6% of the common stock. 1K followers 500+ connections. ROCKVILLE, Md.-- ( BUSINESS WIRE )--Immunomic Therapeutics, Inc., ("ITI") a privately-held clinical-stage biotechnology company pioneering the . 301-968-3501 Melody Carey GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. Internally, we are able to supply the R&D Team with UNITE products in a timely manner for their ongoing oncology studies. The Company has built a pipeline leveraging UNITE with programs in oncology, animal health, infectious disease, and allergy. Company Type For Profit. ICT has established a broad portfolio of CAR-T products to treat cancer patients. 28 Employees . SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Headquarters Location. Jan 2006 - Present17 years 2 months. Find More Contacts for Immunomic Therapeutics, Diversity Spotlight (US Headquarters Only). No.93, Zhongyang Rd., Xindian Dist., New Taipei City 231, Taiwan. Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.
